MDM2 Inhibitor Milademetan in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
J. Clin. Oncol 2023 Jan 20;[EPub Ahead of Print], MM Gounder, TM Bauer, GK Schwartz, AM Weise, P LoRusso, P Kumar, B Tao, Y Hong, P Patel, Y Lu, A Lesegretain, VG Tirunagaru, F Xu, RC Doebele, DS HongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.